Heron Therapeutics (NASDAQ: HRTX) reported Q4 EPS of ($0.17), $0.15 better than the analyst estimate of ($0.32). Revenue for the quarter came in at $30.03 million versus the consensus estimate of $27.24 million.

For earnings history and earnings-related data on Heron Therapeutics (HRTX) click here.